International Best Researcher Award in research and excellence in Pharmaceutical Science
Pravinkumar Darji was honored with “International Best Researcher Award” at the International Science and Technology Awards Congress 2025 (IISTAC 2025) In March 2025, Pravinkumar Darji was bestowed with the “International Best Researcher Award” for outstanding professional achievement in Research and Excellence in Pharmaceutical Science at the International Science and Technology Awards Congress 2025 (IISTAC 2025). Mr. Darji possesses more than 15 years of experience as a researcher in renowned pharmaceutical companies like Exemplify Biopharma Inc. at USA, Aavis Pharmaceuticals at USA and Zydus Lifescience Limited at India and has successfully developed novel drug abuse-deterrent technology in research and development. Mr. Darji’s work is underscored by the pressing need to combat the opioid crisis, a significant public health concern in the United States. His innovative research in developing abuse-deterrent formulations represents a crucial step towards reducing the misuse and abuse of prescription drugs. This work is particularly important given the severe consequences of opioid addiction and overdose, which have reached crisis levels in the country. Moreover, Mr. Darji’s advancements in novel drug delivery systems, such as the Single Layer Osmotic Controlled Release tablets, offer substantial benefits in terms of drug efficacy and patient compliance. This study also demonstrated the feasibility of developing a single-layer osmotic controlled release tablet with a high dosage of a water-insoluble medication. These innovations have the potential to transform therapeutic approaches and improve health outcomes for many patients. Mr. Darji’s innovative SCOP tablet design, which enables controlled drug release for low-soluble drugs. This design has been successfully demonstrated to deliver drugs at zero-order rates for up to 12 hours, with over 90% release within 24 hours. Mr. Darji’s distinguished status in the scientific community, noting that his innovative contributions, such as the development of Single Layer Osmotic Controlled Release tablets, have greatly influenced both regional and international counterparts. Patent Registration 1: Federal Republic of Germany, Certificate on the Registration of Utility Model No. 20 2024 102 831 for his liposomal formulation of Hydroxyurea, which presents a stable, injectable formulation designed to enhance drug bioavailability while minimizing systemic toxicity. Patent Registration 2: Federal Republic of Germany, Certificate on the Registration of Utility Model No. 20 2024 103 209 for his indole derivative-based formulation for targeted cancer treatment, which underscores his innovative contributions to developing targeted therapies. Mr. Darji has published more than 16 research paper and reviewed more than 57 manuscripts as reviewer in more than 10 International Journals. His noteworthy and exceptional scientific contribution to the pharmaceutical industry, for which he most recently received the “International Achievers Award 2024”. The distinguished research of Mr. Darji not only helped the advancement of the pharmaceutical profession but also the growth of the US economy.